SEARCH

SEARCH BY CITATION

References

  • 1
    C.M.S. Le prélévement et la greffe en France. Paris: Etablissement Français des Greffes: 1997.
  • 2
    Taube DH, Cameron JS, Ogg CS et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984; i: 824826.
  • 3
    Hiesse C, Kriaa F, Rousseau P et al. Immunoadsorption of anti HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant 1992; 7: 944951.
  • 4
    Glotz D, Haymann J-P, Sansonetti N et al. Suppression of allo-anti HLA antibodies by high dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335337.
  • 5
    Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553562.
  • 6
    Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 10381039.
  • 7
    Wadstrom J, Gannedahl G, Bersztel A, Bengtsson M, Nattorp K, Mulec H. Successful kidney transplantation after suppression of HLA alloantibodies with intravenous immunoglobulin in a highly sensitized patient. Transplant Proc 1995; 27: 34633464.
  • 8
    John RK, Lietz E, Burke J et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: 1122911235.
  • 9
    Feinstein LC, Seidel K, Jocum J et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 1999; 5: 369378.
  • 10
    Abdel-Mageed A, Graham-Pole J, Del Rosario ML et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant 1999; 23: 929932.
  • 11
    Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 16331639.
  • 12
    Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins for intravenous use (IVIg). Transplant Proc 1995; 27: 10381039.
  • 13
    McIntyre JA, Higgins N, Britton R et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996; 62: 691693.
  • 14
    Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998; 51(Suppl. 5): S2S8.
  • 15
    Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 15311536.
  • 16
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.